Frontier IP Group PLC (AIM:FIPP, OTC:FGPPF) portfolio company The Vaccine Group (TVG) CEO Jeremy Salt speaks to Proactive after announcing that TVG has recently completed vaccine projects both for Streptococcus suis and for Lassa fever.
Salt reveals a remarkable feature of the Lassa fever vaccine and looks ahead to what investors can expect from TVG during the coming year.